Jakafi 10 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FGEP8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,094
Award facts
- Contract value 100% obligated
- $37,094.43 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $37,094.43 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi (ruxolitinib) 10 mg tablets in a quantity of 60 units. This firm fixed-price delivery order, awarded on December 8, 2025, with an ultimate completion date of December 9, 2025, carries no set-aside designation, indicating the vendor competed in an unrestricted procurement. The award was issued without subcontractor involvement and will be performed at the vendor's Park Ridge location.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply across the Department of Defense's global military healthcare system. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support recurring medical supply needs. DMS Pharmaceutical Group's established performance across numerous delivery orders and its status as a critical pharmaceutical supplier within the federal military medical supply chain demonstrate its capability to fulfill specialized pharmaceutical requirements for defense healthcare operations worldwide.
Quick answers
Who was awarded contract SPE2DR26FGEP8?
SPE2DR26FGEP8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FGEP8 worth?
The government has obligated $37,094 on SPE2DR26FGEP8.
Is contract SPE2DR26FGEP8 an order under another contract?
Yes. SPE2DR26FGEP8 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGEP8 competed?
The extent of competition for SPE2DR26FGEP8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award